T2 Biosystems to Participate in Sepsis Alliance Summit
September 16 2020 - 8:00AM
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid
detection of sepsis-causing pathogens, today announced that it is
participating in the virtual, inaugural Sepsis Alliance Summit
taking place September 16-17, 2020, through a sponsorship and
virtual booth in honor of Sepsis Awareness Month (September).
The Summit was designed by the Sepsis Alliance, the leading
sepsis organization in the U.S. and working in all 50 states to
save lives and reduce suffering from sepsis, to explore an array of
sepsis-related topics in health care as well as highlight the needs
for more sensitive and rapid diagnostics tests for
COVID-19. T2 Biosystems’ virtual booth will feature
information on the Company’s products for the rapid detection of
sepsis-causing pathogens – directly from whole blood and without
the need to wait for blood culture – as well as for the detection
of SARS-CoV-2, the virus responsible for COVID-19 infections.
“Sepsis Awareness Month helps to save lives by raising awareness
of sepsis, the leading cause of death in U.S. hospitals. Sepsis
costs the U.S. healthcare system nearly $41 billion annually and
results in the death of approximately 270,000 Americans each year,”
said John Sperzel, President and Chief Executive Officer of T2
Biosystems. “We are proud to join the Sepsis Alliance and industry
members in critical discussions about the importance of rapid
diagnostic technology, which holds the key to improving outcomes
for patients with bloodstream infections, sepsis, and the COVID-19
virus which can lead to sepsis.”
Weeks prior, T2 Biosystems received Emergency Use Authorization
from the U.S. Food and Drug Administration (FDA) for its COVID-19
molecular diagnostic test, the T2SARS-CoV-2™ Panel. The panel
runs on the Company’s FDA-cleared and fully-automated
T2Dx® Instrument, which is capable of performing seven tests
simultaneously.
The T2Dx Instrument can also run the Company’s FDA-cleared
T2Bacteria® Panel and T2Candida® Panel. These panels are
the only FDA-cleared assays for the detection of sepsis-causing
bacterial and fungal pathogens directly from whole blood in three
to five hours, without the need to wait days for blood culture
results. By providing quicker results, the panels enable clinicians
to target therapy faster for their patients suspected of sepsis,
often before the second dose of antimicrobial is administered,
leading to better patient outcomes, improved antimicrobial
stewardship, and reductions in length of stay in the hospital.
About T2 Biosystems T2 Biosystems, a
leader in the rapid detection of sepsis-causing pathogens, is
dedicated to improving patient care and reducing the cost of care
by helping clinicians effectively treat patients faster than ever
before. T2 Biosystems’ products include the T2Dx® Instrument,
T2Candida® Panel, the T2Bacteria® Panel, the
T2ResistanceTM Panel, and the T2SARS-CoV-2™ Panel and are
powered by the proprietary T2 Magnetic Resonance (T2MR®)
technology. T2 Biosystems has an active pipeline of future
products, including the T2CaurisTM Panel, and T2Lyme TM Panel, as
well as additional products for the detection of bacterial and
fungal pathogens and associated antimicrobial resistance markers,
as well as biothreat pathogens.
Forward-Looking Statements This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements
contained in this press release that do not relate to matters of
historical fact should be considered forward-looking statements,
including, without limitation, statements regarding the potential
impact of rapid diagnostics on outcomes for patients with
bloodstream infections, sepsis and the COVID-19 virus,the T2Dx®
Instrument’s simultaneous testing capacity, the benefit of early
identification of bacterial or fungal infections, as well as
statements that include the words “expect,” “intend,” “plan”,
“believe”, “project”, “forecast”, “estimate,” “may,” “should,”
“anticipate,” and similar statements of a future or forward looking
nature. These forward-looking statements are based on management's
current expectations. These statements are neither promises nor
guarantees, but involve known and unknown risks, uncertainties and
other important factors that may cause actual results, performance
or achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements, including, but not limited to, (i) any
inability to (a) realize anticipated benefits from commitments,
contracts or products; (b) successfully execute strategic
priorities; (c) bring products to market; (d) expand product usage
or adoption; (e) obtain customer testimonials; (f) accurately
predict growth assumptions; (g) realize anticipated revenues; (h)
incur expected levels of operating expenses; or (i) increase the
number of high-risk patients at customer facilities; (ii) failure
of early data to predict eventual outcomes; (iii) failure to
make or obtain anticipated FDA filings or clearances within
expected time frames or at all; or (iv) the factors discussed under
Item 1A. "Risk Factors" in the Company's Annual Report on Form 10-K
for the year ended December 31, 2019, filed with the U.S.
Securities and Exchange Commission, or SEC, on March 16, 2020, and
other filings the Company makes with the SEC from time to
time. These and other important factors could cause actual
results to differ materially from those indicated by the
forward-looking statements made in this press release. Any such
forward-looking statements represent management's estimates as of
the date of this press release. While the Company may elect to
update such forward-looking statements at some point in the future,
unless required by law, it disclaims any obligation to do so, even
if subsequent events cause its views to change. Thus, no one should
assume that the Company’s silence over time means that actual
events are bearing out as expressed or implied in such
forward-looking statements. These forward-looking statements
should not be relied upon as representing the Company's views as of
any date subsequent to the date of this press release.
Media Contact: Gina Kent, Vault
Communications gkent@vaultcommunications.com
610-455-2763
Investor Contact: Philip Trip Taylor, Gilmartin
Group philip@gilmartinIR.com 415-937-5406
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Mar 2024 to Apr 2024
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Apr 2023 to Apr 2024